secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001493152-25-025893
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity to present CyPath Lung data showing Stage 1A detection in challenging cases at ACS NLCRT Dec 8
--------------------------------------------------------------------------------

- CyPath Lung identified Stage 1A lung cancer in three patients with atypical presentations.
- Poster session at American Cancer Society National Lung Cancer Roundtable on Dec 8, 2025, 2:35-3:15 p.m. ET.
- Chief Medical Officer Gordon Downie presenting cases from Titus Regional Hospital Lung Nodule Clinic.
- Test uses flow cytometry and AI on sputum; prior study showed 92% sensitivity and 87% specificity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225025893/0001493152-25-025893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225025893/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-025893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer